9 Meters Biopharma EBIT

The latest EBIT for NMTR is $-43M as of March 2023. That compares with $-38M in the prior-year period — down 15.5% year over year. That is below the Technology sector average of $14T. Investors often review this figure alongside 9 Meters Biopharma's historical trend and sector peers before judging valuation or financial health.

Over the past year, NMTR's EBIT moved from $-38M to $-43M — a 15.5% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in 9 Meters Biopharma's operating scale or balance-sheet position.

Against Technology companies, NMTR currently prints $-43M for EBIT, while the sector average sits near $14T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at 9 Meters Biopharma's growth, margins, and balance sheet.

A EBIT figure of $-43M for NMTR is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Technology average is about $14T. Explore the charts below for those layers of context.

After noting NMTR's EBIT ($-43M), review year-over-year change from $-38M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.